IAI Versus Sham as Prophylaxis Against Conversion to Neovascular AMD
NCT02462889 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 128
Last updated 2025-11-14
Summary
This is a prospective, single-blind, randomized study to evaluate intravitreal aflibercept injection (IAI) versus sham as prophylaxis against conversion to neovascular age-related macular degeneration (AMD) in "high-risk" subjects.
Conditions
- Age-Related Macular Degeneration
Interventions
- DRUG
-
Intravitreal aflibercept injection
Intravitreal aflibercept injection
- DRUG
-
Sham injection
Sponsors & Collaborators
- collaborator INDUSTRY
-
Jeffrey S Heier
lead OTHER
Principal Investigators
-
Jeffrey S Heier, MD · Ophthalmic Consultants of Boston
Study Design
- Allocation
- RANDOMIZED
- Purpose
- PREVENTION
- Masking
- SINGLE
- Model
- PARALLEL
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2015-06-30
- Primary Completion
- 2019-03-31
- Completion
- 2019-03-31
Countries
- United States
Study Locations
More Related Trials
-
Observational Study to Assess Intravitreal Aflibercept Injections Used in a "Treat and Extend" Regimen in Treatment-naïve Wet Age-related Macular Degeneration Patients
NCT03382587 ·Status: COMPLETED
-
Study to Assess Best Corrected Visual Acuity (BCVA) in Patients With Neovascular Age-Related Macular Degeneration (AMD) Who Are Administered VEGF Trap-Eye (Intravitreal Aflibercept Injection)
NCT01722045 ·Status: COMPLETED ·Phase: PHASE4
-
Open-label Extension Study of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) in Neovascular ("Wet") Age-related Macular Degeneration (AMD)
NCT00964795 ·Status: COMPLETED ·Phase: PHASE3
-
Intravitreal Aflibercept for Retinal Non-Perfusion in Proliferative Diabetic Retinopathy
NCT02863354 ·Status: COMPLETED ·Phase: PHASE2
-
Aflibercept Injection Into the Vitreous Body of the Eye: Study to Learn More About Patient Relevant Outcomes, Real World Treatment Patterns and How Well the Treatment Works for Patients Suffering From Abnormal Growth of New Blood Vessels Under the Retina.
NCT03714308 ·Status: COMPLETED
-
Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection
NCT02713204 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Intravitreal REGN2176-3 in Participants With Neovascular ("Wet") Age-Related Macular Degeneration (AMD)
NCT02418754 ·Status: TERMINATED ·Phase: PHASE2
-
A Pharmacokinetic stuDy of intRavitreal Aflibercept Injection in Vitrectomized and Non-vitrectomized Eyes With Diabetic Macular Edema
NCT04588948 ·Status: WITHDRAWN ·Phase: PHASE2
-
Study of the Effects of High Dose Aflibercept Injected Into the Eye of Patients With an Age-related Disorder That Causes Loss of Vision Due to Growth of Abnormal Blood Vessels at the Back of the Eye
NCT04423718 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of RTH258 Versus Aflibercept - Study 1
NCT02307682 ·Status: COMPLETED ·Phase: PHASE3
-
An Observational Study to Investigate the Use of Aflibercept 8 mg to Treat Adult Patients With Neovascular Age-Related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME) in a Real-World Setting
NCT06398080 ·Status: WITHDRAWN
-
A Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME)
NCT06491914 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Intense Treatment Regimen With Intravitreal Aflibercept Injection
NCT03594461 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
A Study to Learn How Well Aflibercept Injected Into the Eye Works and How Safe it is When Given in Customized Treatment Intervals in Patients With an Eye Disease Called Neovascular Age-related Macular Degeneration After Start of Treatment
NCT05473715 ·Status: TERMINATED ·Phase: PHASE4
-
Aflibercept in Polypoidal Choroidal Vasculopathy
NCT02120950 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy and Safety of Aflibercept in Patients With Neovascular Age-related Macular Degeneration
NCT05587062 ·Status: COMPLETED ·Phase: PHASE3
-
4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration
NCT06864988 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Evaluation of IBI302 Injection in nAMD or DME
NCT05961007 ·Status: SUSPENDED ·Phase: PHASE1/PHASE2
-
Treat and Extend Therapy Study Using Intravitreal Aflibercept for Patients Exited From Protocol VGFT-OD 0910
NCT01961414 ·Status: UNKNOWN ·Phase: PHASE4
-
Efficacy and Safety of Three Different Aflibercept Regimens in Subjects With Diabetic Macular Edema (DME)
NCT02818998 ·Status: COMPLETED ·Phase: PHASE3
-
On-label tReatment With Intravitreal Aflibercept injectiOn for Patients With Persistent Pigment epitheliaL Detachments in Neovascular Age Related Macular Degeneration (AMD)
NCT01670162 ·Status: UNKNOWN ·Phase: PHASE4
-
A Safety and Efficacy Study of DE-120 Injectable Solution for Age-related Macular Degeneration
NCT02401945 ·Status: COMPLETED ·Phase: PHASE2
-
Japanese Treat and Extend Study of Aflibercept in Neovascular Age-related Macular Degeneration
NCT02305238 ·Status: COMPLETED ·Phase: PHASE4
-
Study to Assess the Clinical Efficacy and Safety of Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) in Patients With Branch Retinal Vein Occlusion (BRVO)
NCT01521559 ·Status: COMPLETED ·Phase: PHASE3
-
Evaluate the Effectiveness of Intravitreal (IVT) Aflibercept Injection in Clinical Practice in naïve Patients With Neovascular Age-related Macular Degeneration (nAMD)
NCT03411941 ·Status: COMPLETED